HC Wainwright reaffirmed its “buy” rating on Immunovant (NASDAQ:IMVT) with a $35.00 price objective, suggesting a potential upside of 27.32%. Other analysts have also adjusted their ratings and price targets for the biopharmaceutical company, resulting in a consensus “Moderate Buy” rating and a price target of $31.11. Insider selling and institutional investor activity have also been noted, with the stock currently trading at $27.49.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Immunovant (NASDAQ:IMVT) Given Buy Rating at HC Wainwright
HC Wainwright reaffirmed its “buy” rating on Immunovant (NASDAQ:IMVT) with a $35.00 price objective, suggesting a potential upside of 27.32%. Other analysts have also adjusted their ratings and price targets for the biopharmaceutical company, resulting in a consensus “Moderate Buy” rating and a price target of $31.11. Insider selling and institutional investor activity have also been noted, with the stock currently trading at $27.49.